Skip to content

Orange Juice Consumption in Patients With Hepatitis C

Orange Juice as Dietary Source of Antioxidants for Patients With Hepatitis C Under Antiviral Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03026569
Enrollment
43
Registered
2017-01-20
Start date
2012-05-31
Completion date
2012-09-30
Last updated
2017-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Infection

Keywords

orange juice, chronic hepatitis C, biochemical markers, oxidative stress, nutritional status, antioxidants

Brief summary

This study aimed to verify whether orange juice, source of citrus flavonoids and vitamin C, may contribute to the treatment of patients with chronic hepatitis C.

Detailed description

Forty-three patients with chronic hepatitis C who were being treated with pegylated interferon combined with ribavirin, according to the Clinical Protocol and Therapeutic Guidelines for Viral Hepatitis C and Co-infections of the Brazilian Health Ministry were randomly divided into two parallel groups: (1) orange juice (n = 23), which were supplemented with orange juice (500 mL/d) for 8 weeks; (2) control group (n = 20) composed of patients that were not drinking orange juice regularly. The recruitment process began in February 2012, the intervention was carried out from May 2012 to July 2012, and the data analysis started in September 2012. The sample number took into account variances on total cholesterol with a type I error α = 0.05 and a type II error β = 0.2 (80% power) (Dourado et al., 2015). The minimum sample size should have 20 individuals per group (n = 40), considering an approximately 15% dropout rate. Primary and secondary endpoints were the reduction of total cholesterol and modification of biochemical markers, respectively. Kolmogorov Smirnov and Levene test assessed normality and homogeneity of data, respectively. Assessment of the data was performed in all participants on the first and last day of the experiment. All the parameters were compared between the juice group and the control group using General Linear Model of Repeated Measures Analysis. Differences in baseline patients' characteristics between the two groups were analyzed by One-way analysis of variance (ANOVA). The LSD signed rank post-test was used to assess significant changes in parameters after the start of treatment in each group, and the differences were considered statistically significant at p \< 0.05.

Interventions

The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.

Sponsors

São Paulo State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Detection of circulating HCV RNA * Negative HBV surface antigen * Negative antibodies to HIV

Exclusion criteria

* Co-infection with hepatitis B virus (HBV) * Co-infection with hepatitis A virus (HAV) * Co-infection with human immunodeficiency virus (HIV) * Presence of diabetes mellitus, * Presence of ascites * Elevation in serum ferritin levels

Design outcomes

Primary

MeasureTime frame
Total cholesterol8 weeks

Secondary

MeasureTime frame
Body mass index8 weeks
% body fat8 weeks
Waist circumference8 weeks
Glucose8 weeks
Insulin8 weeks
HOMA-IR8 weeks
LDL-C8 weeks
HDL-C8 weeks
Body mass8 weeks
CRP8 weeks
alkaline phosphatase8 weeks
AST8 weeks
ALT8 weeks
gamma-GT8 weeks
TBARS8 weeks
ABTS8 weeks
Triglycerides8 weeks

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026